OnKure Therapeutics

Health Care · Medical AI
Data updated Nov 21, 2026Money ledger: 14 records from 1 sourceFiled 14Full reportReport a mistake

Facts

as of Nov 21, 2026

OnKure Therapeutics - Writing the Next Chapter in Precision Medicines.

Legal name
OnKure Therapeutics, Inc.
Headquarters
Boulder, United States
Employees
51-200estimated range
Legal entities
2 in 1 country
Listing
NASDAQ: OKUR
Official records
Wikidata Q123420969

These are the key facts about OnKure Therapeutics on Alion as of Nov 21, 2026. OnKure Therapeutics is headquartered in Boulder, United States. It has raised $282.6M in 14 funding rounds. The latest round is Venture - Series Unknown of $65M, announced in 2024.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

OnKure Therapeutics has $282.6M paid in by investors, lenders and donors.

$282.6MPaid in
Money innewest first
Equity raised
Oct 2024 · Venture round
$65MPaid
Equity raised
Mar 2023 · Venture round
$53.8MPaid
Equity raised
Mar 2021 · Venture round
$56.6MPaid
11 more records: amounts, dates and sources of every round, loan and commitmentProUnlockor this company alone for 30 days · 50 credits
Money by yearUSD, rounds and grants
2024$65M1 record
2023$53.8M1 record
2021$56.6M1 record
2020$53.1M4 records
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".

OnKure Therapeutics operates through 2 legal entities in 1 country.

Legal entities2 in 1 country
OnKure Therapeutics, Inc.
operator
US
OnKure, Inc.
operator
US
Holders and shares as each register or filing states them.

Products

Products →

OnKure Therapeutics has 3 clinical trials on record, 1 under way.

Clinical trials
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
phase 1 · under way · 200 participants · Advanced Cancer; Breast Cancer; Advanced Solid Tumors; PI3K Gene Mutation
Feb 2024
NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutate…
phase 2 · completed · 36 participants · RAS Mutation; NRAS Gene Mutation; Melanoma
May 2022
A Study of OKI-179 in Patients With Solid Tumors
phase 1 · completed · 34 participants · Advanced Solid Tumors
May 2019
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.

OnKure Therapeutics in public registers.

Legal entity active
OnKure Therapeutics, Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Patents
9
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Footprint

Hiring in 1 city in 1 country.

1Cities
1Countries
SiteTypeOpen rolesHires most forEngineering
Boulder United StatesHeadquarters0
Source: office addresses in postings and company registers

Milestones

Nov 2026
Went public NASDAQ: OKUR
Oct 4, 2024
Mar 24, 2023
Each milestone is dated by its source: registers, filings, the press